Regeneron Pharmaceuticals, Inc. REGN
788.04
(7.98)
(1.00%)
as of 25 Sep
- Market cap
- $81.3B
- P/E
- 18.8×
Follow REGN
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Regeneron Pharmaceuticals, Inc. (REGN) Free cash flow
Regeneron Pharmaceuticals, Inc.'s free cash flow for fiscal 2025 was $3.8B, up 5.79% from $3.6B in fiscal 2024. Over the twelve months to 30 June 2026 it was $3.6B. Over the past ten years it has ranged from $652.8M (fiscal 2015) to $6.5B (fiscal 2021); the current reading is higher than 91% of that period. Regeneron Pharmaceuticals, Inc. ranks 2nd of 613 Biotechnology companies by free cash flow.
Free cash flow, annual
Annual
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $3.8B | 5.79% |
| FY2024 | $3.6B | (2.96%) |
| FY2023 | $3.7B | 7.93% |
| FY2022 | $3.4B | (47.96%) |
| FY2021 | $6.5B | 225.90% |
| FY2020 | $2.0B | 0.15% |
| FY2019 | $2.0B | 10.40% |
| FY2018 | $1.8B | 75.16% |
| FY2017 | $1.0B | 6.21% |
| FY2016 | $974.0M | 49.19% |
Quarterly
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | $521.8M | (34.73%) |
| Mar 2026 | $799.4M | (9.16%) |
| Dec 2025 | $880.0M | (35.95%) |
| Sep 2025 | $1.4B | 86.28% |
| 42 more quarters | Free account |
Against its own ten years
Low $652.8M
High $6.5B
Ten-year median
$2.0B
Current reading's percentile
91
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| VRTX Vertex Pharmaceuticals Incorporated compare | $3.8B |
| REGN Regeneron Pharmaceuticals, Inc. | $3.6B |
| ARGX argenex SE compare | $1.4B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $1.3B |
| RPRX Royalty Pharma PLC compare | $1.3B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $819.9M |
| INSM Insmed, Inc. compare | −$807.7M |
| RVMD Revolution Medicines, Inc. compare | −$1.2B |
| MRNA Moderna, Inc. compare | −$1.2B |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on REGN
- Revenue
- Net income
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement